U.S. Pharma Stock News

If you are looking at Xeris Biopharma Holdings and wondering whether the recent excitement still offers fair value, this article will walk you through what the current price might be implying. The stock last closed at US$7.93, with returns of 7.9% over the past week, 14.3% over the past month, 7.9% year to date, and 133.2% over the last year, along with a very large 3 year return that is more than 5x. Recent company news has put a spotlight on Xeris Biopharma Holdings, adding context to...

Bank of America Securities has downgraded Sigma Lithium (SGML) to Underperform, citing ongoing operational delays, liquidity concerns, uncertainty around restarting mining operations, and questions about the timing of expected prepayment funds. See our latest analysis for Sigma Lithium. At a share price of $13.51, Sigma Lithium sits on a 90 day share price return of 116.51% and a 1 year total shareholder return of 15.77%, while the 3 year total shareholder return remains sharply lower. Recent...

In 2025, Agree Realty Corporation invested about US$1.55 billion across 338 retail net lease properties in 41 states, increased its exposure to investment‑grade tenants, and ended the year with over US$2.00 billion in liquidity supported by an undrawn US$350.00 million term loan. This combination of high investment‑grade rent exposure, sizable new investments at around 7.2% cap rates, and expanded funding capacity materially reshapes how investors may assess the REIT’s income stability and...

If you are wondering whether ATI's recent share price puts it on sale or already prices in a lot of good news, you are asking the right question for any valuation focused review. ATI's stock has moved to US$122.30, with returns of 2.6% over the past week, 16.8% over the past month, 2.6% year to date, 122.0% over the last year and a very large gain over the past five years. Recent news flow around ATI has focused on the business rather than one off events. This helps set a clearer backdrop...

Hartford Insurance Group (HIG) has opened a new technology hub in Columbus, Ohio. The hub brings together around 75 employees focused on AI, cloud architecture, and broader technology transformation work for the insurer. See our latest analysis for Hartford Insurance Group. At a share price of US$136.26, Hartford Insurance Group has seen a 4.62% 1 month share price return and a 5.61% 3 month share price return. Its 1 year total shareholder return of 30.34% and 5 year total shareholder return...

With a median price-to-sales (or "P/S") ratio of close to 0.5x in the Specialty Retail industry in the United States...

Steel Partners Holdings (SPLP) is on investors’ radar after recent share price moves, with the stock showing double digit returns over the month and the past 3 months, prompting fresh interest in its diversified operations. See our latest analysis for Steel Partners Holdings. That recent momentum sits on top of a solid year, with a 13.83% year to date share price return and a 1 year total shareholder return of 17.94%. The 5 year total shareholder return is a little under 3x. If SPLP’s move...

If you are wondering whether MACOM Technology Solutions Holdings at around US$174.87 is still a good deal or already pricing in a lot of optimism, you are not alone. The stock has been relatively flat year to date with a 0.1% decline. Yet it is up 31.6% over 1 year and 172.5% over 3 years, which hints that the market’s view on its future potential and risk has shifted over time. Recent attention on MACOM has centered around its role in semiconductors for high performance applications and how...

EyePoint Pharmaceuticals recently provided a corporate update outlining progress for its lead retinal therapy DURAVYU, including ongoing Phase 3 trials in wet age-related macular degeneration and preparations for a Phase 3 start in diabetic macular edema, as well as work toward a potential future regulatory filing in the US. This update underscored how DURAVYU sits at the center of EyePoint’s efforts to transition from minimal post-exit revenues to a focused retinal disease platform with a...

We wouldn't blame Gulfport Energy Corporation ( NYSE:GPOR ) shareholders if they were a little worried about the fact...

If you are wondering whether Humana’s current share price fairly reflects its long term prospects, you are not alone. This article is designed to help you think through that question clearly. Humana’s stock most recently closed at US$276.85, with returns of 4.7% over the last week, 7.9% over the last month, 4.7% year to date, 4.3% over the last year, and longer term returns of a 41.8% decline over three years and a 28.8% decline over five years. Recent attention on Humana has centered on how...

Blackstone Mortgage Trust (BXMT) is drawing fresh attention as investors reassess the stock after a period of mixed short term returns, including a decline over the past month alongside a positive move over the past three months. See our latest analysis for Blackstone Mortgage Trust. At a share price of $19.45, Blackstone Mortgage Trust has seen a 4.42% 1 month share price decline. However, a 90 day share price return of 8.30% alongside a 1 year total shareholder return of 25.03% suggests...

Regency Centers (REG) has drawn fresh attention after recently closing at US$69.72, with short term returns mixed over the past week, month, and 3 months. This has prompted a closer look at its underlying fundamentals. See our latest analysis for Regency Centers. The recent pullback, with a 1 day share price return of a 1.27% decline from US$69.72, sits against a year to date share price return of 2.59% and a 1 year total shareholder return of 5.47%. This suggests momentum has been steady...

Looking at Silence Therapeutics plc's ( NASDAQ:SLN ) insider transactions over the last year, we can see that insiders...

Hurco Companies (HURC) closed FY 2025 with fourth quarter revenue of US$45.5 million and a basic EPS loss of US$0.48, while trailing twelve month revenue stood at US$178.6 million against a basic EPS loss of US$2.34. Over recent periods, the company has seen quarterly revenue move between US$40.9 million and US$53.7 million, with basic EPS losses ranging from US$0.22 to US$1.47. This sets a clear backdrop of pressure on profitability that keeps margins front and center for investors assessing...

LENZ Therapeutics (LENZ) shares are in focus after the company signed an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO to register and commercialize its VIZZ eye drop for presbyopia across multiple Middle Eastern markets. See our latest analysis for LENZ Therapeutics. The distribution deal comes after a weak run for the stock, with a 30 day share price return of 40.62% and a 90 day share price return of 61.67%, while the 1 year total shareholder return sits at...

Crescent Energy (CRGY) has been drawing attention after a mixed return profile, with the share price down about 17% over the past month but remaining roughly flat over the past 3 months and weaker over the past year. See our latest analysis for Crescent Energy. At the latest share price of $8.12, Crescent Energy’s recent performance has been weak, with a 7 day share price return of 4.6% decline and a 1 year total shareholder return of 46.2% decline, suggesting momentum has been fading rather...

If you are wondering whether JBT Marel at US$156.04 is still a sensible entry point or more of a hold, the next sections will walk through what the current price may be implying about value. The stock has recorded returns of 3.6% over the past week, 1.5% over the last month, 3.6% year to date and 28.5% over the past year, with a 55.0% return over three years and 25.8% over five years. These figures can affect how investors think about both upside potential and downside risk. Recent attention...

What Lilly’s AI tie-up could mean for Revvity stock Revvity (RVTY) just announced a collaboration with Eli Lilly that puts Lilly’s TuneLab AI and machine learning models inside the Revvity Signals platform, directly tying the stock story to AI-enabled drug discovery workflows. The move builds on Revvity’s Signals Xynthetica and Models-as-a-Service offerings. It gives biotech customers a way to apply Lilly’s predictive models to their own data while keeping proprietary information protected...

Wondering whether Brown & Brown at around US$80.64 is offering fair value right now, or if the market is mispricing it? This article walks through that question in plain English. The stock is up 3.9% over the last week and 4.0% over the last month, but that comes after a 20.4% decline over the past year, even with 3 year and 5 year returns of 34.2% and 80.1% respectively. These moves have kept Brown & Brown on many investors' radars, as they reassess what the recent share price says about...

Shares of Global Business Travel Group (GBTG) moved after parent investor Certares partnered with Italian rail operator FS to promote high speed rail over short haul flights, a development tied closely to rising sustainability priorities. See our latest analysis for Global Business Travel Group. The sustainability focused rail partnership arrives at a time when GBTG’s share price, last closing at US$8.15, has a 7 day share price return of 8.38% and a 90 day share price return of 8.09%. The 3...

Interface (NASDAQ:TILE) has had a great run on the share market with its stock up by a significant 15% over the last...

CVD Equipment Corporation ( NASDAQ:CVV ) shareholders have had their patience rewarded with a 36% share price jump in...

Angi Inc.'s ( NASDAQ:ANGI ) price-to-earnings (or "P/E") ratio of 17.2x might make it look like a buy right now...